Johnson & Johnson Acquires New Shares in Clearside Biomedical, Inc. (NASDAQ:CLSD)

Johnson & Johnson bought a new position in shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 82,481 shares of the company’s stock, valued at approximately $105,000. Clearside Biomedical makes up 0.0% of Johnson & Johnson’s portfolio, making the stock its 19th largest position. Johnson & Johnson owned 0.11% of Clearside Biomedical at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in CLSD. SG Americas Securities LLC purchased a new stake in Clearside Biomedical in the first quarter valued at approximately $49,000. XTX Topco Ltd raised its position in Clearside Biomedical by 172.2% during the 2nd quarter. XTX Topco Ltd now owns 54,313 shares of the company’s stock valued at $71,000 after purchasing an additional 34,359 shares during the last quarter. Assenagon Asset Management S.A. purchased a new stake in Clearside Biomedical in the second quarter worth $368,000. Renaissance Technologies LLC boosted its stake in shares of Clearside Biomedical by 6.6% during the 2nd quarter. Renaissance Technologies LLC now owns 582,689 shares of the company’s stock valued at $757,000 after purchasing an additional 35,900 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Clearside Biomedical by 14.5% during the 1st quarter. Vanguard Group Inc. now owns 2,490,796 shares of the company’s stock worth $3,811,000 after acquiring an additional 314,480 shares during the period. 18.75% of the stock is owned by institutional investors.

Insider Buying and Selling at Clearside Biomedical

In other Clearside Biomedical news, insider Ngai Hang Victor Chong bought 36,500 shares of Clearside Biomedical stock in a transaction on Friday, November 1st. The stock was acquired at an average cost of $1.00 per share, with a total value of $36,500.00. Following the completion of the acquisition, the insider now owns 100,000 shares in the company, valued at approximately $100,000. This represents a 57.48 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 9.20% of the company’s stock.

Clearside Biomedical Stock Up 0.9 %

Shares of CLSD stock traded up $0.01 during mid-day trading on Wednesday, hitting $1.09. The company’s stock had a trading volume of 4,131 shares, compared to its average volume of 394,991. Clearside Biomedical, Inc. has a 52-week low of $0.92 and a 52-week high of $2.12. The business has a 50-day moving average price of $1.16 and a 200 day moving average price of $1.17.

Clearside Biomedical (NASDAQ:CLSD) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.04. The company had revenue of $1.04 million for the quarter, compared to analysts’ expectations of $0.25 million. During the same period in the previous year, the business earned ($0.15) EPS. Equities analysts forecast that Clearside Biomedical, Inc. will post -0.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Chardan Capital reissued a “buy” rating and set a $6.00 price objective on shares of Clearside Biomedical in a research report on Friday, November 15th. Needham & Company LLC restated a “buy” rating and issued a $6.00 price objective on shares of Clearside Biomedical in a report on Wednesday, November 13th. HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Clearside Biomedical in a research note on Thursday, November 14th. Finally, StockNews.com upgraded Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Saturday, November 16th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.33.

Clearside Biomedical Profile

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.